Prioritizing Mental Health in South African Medical Schemes: Challenges and Opportunities

By HEOR Staff Writer

May 1, 2023

Medical schemes in South Africa are prioritizing mental health as a key component of managed care services. In 2019 CMS published a PMB definition guidelines for mental health emergencies.

“It is still concerning that beneficiaries of medical schemes attracted copayments as high as five (5%) for services such as a psychiatry benefit. Prior studies have also found that medical scheme members affected by mental illness and in most cases were discriminated against by funders. There needs to be a concerted effort to reprioritise mental health,” said Willie

A study analysed data from 2014-2018 and found the most prevalent mental disorders in South Africa in 2017 were anxiety and depression. However, only schizophrenia and bipolar mood disorder are the only conditions included in the PMB Chronic Diseases List (CDLs).

It is worrying that mental disorders like depression and anxiety are not covered under PMBs. We need a review of PMBs to include these conditions. A designated medical scheme provider should consider resource scarcity and co-payment rules.

Reference url

Recent Posts

Wegovy HD Approval: A Game Changer in Obesity Treatment and Weight Loss Efficacy

By João L. Carapinha

March 20, 2026

Novo Nordisk announced the Wegovy HD approval by the US Food and Drug Administration (FDA) for Wegovy® HD (semaglutide injection 7.2 mg), a higher-dose formulation showing superior weight loss over the existing 2.4 mg dose in adults with obesity. In the STEP UP trial, this new dose delivered an a...
Milestone Approval of Invasive Brain-Computer Interface Revolutionizes Spinal Cord Injury Treatment
China's National Medical Products Administration (NMPA) has approved the world's first invasive brain-computer interface medical device for market entry. Developed by Borui Kang Medical Technology (Shanghai) Co.,...
Accelerating Patient Access: MHRA NICE Alignment Initiative
MHRA NICE alignment introduces a groundbreaking pathway launching on 1 April 2026, synchronizing the Medicines and Healthcare products Regulatory Agency (MHRA)'s licensing with the National Institute for Health and Care Excellence (NICE)'s value assessments. This enables new medicines to reach pa...